Frontlight ResearchEarly access
Neuromyelitis optica (NMOSD) trials in China
23 of 34 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleSafety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
- Where
- Tianjin
- Age
- 18 years to 60 years
- People
- 27
- Run by
- Tianjin Medical University General Hospital
See details and how to joinNCT07022197 - Phase 3Taking peopleA Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Where
- Guangzhou, Shanghai
- Age
- 2 years to 11 years
- People
- 8 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05199688 · EU 2023-507817-85-00 - Phase 1Taking peopleThe Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders
- Where
- Wuhan
- Age
- 18 years to 65 years
- People
- 69
- Run by
- Tongji Hospital
See details and how to joinNCT06620809 - Phase 3Taking peopleEfficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Where
- Beijing, Chengdu, Dongguan, Jinan, Shanghai, Shijiazhuang, Taiyuan, Wenzhou, Wuhan
- Age
- 18 years to 130 years
- People
- 19
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07557420 - Phase 2Not yet taking people in ChinaEfficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
- Where
- Beijing
- Age
- 18 years to 74 years
- People
- 60
- Run by
- Peking University People's Hospital
See details and how to joinNCT07809724 - Phase 4Not yet taking people in ChinaCrisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
- Where
- Beijing, Changchun, Chongqing, Harbin, Hohhot, Kunming, Shenyang, Ürümqi, Xi'an
- Age
- 18 years to 75 years
- People
- 110
- Run by
- Tang-Du Hospital
See details and how to joinNCT07699770 - Phase 1Not yet taking people in ChinaA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Where
- Qingdao
- Age
- 18 years to 70 years
- People
- 18
- Run by
- The Affiliated Hospital of Qingdao University
See details and how to joinNCT07676266 - Early phase 1Not yet taking people in ChinaThe Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
- Where
- Beijing
- Age
- 18 years to 65 years
- People
- 18
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT07592754 - Phase 3Taking peopleModified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
- Where
- Tianjin
- Age
- 18 years to 80 years
- People
- 198
- Run by
- Tianjin Medical University General Hospital
See details and how to joinNCT07420296 - Phase 1Taking peopleSafety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 6
- Run by
- Tongji Hospital
See details and how to joinNCT07526493 - Early phase 1Taking peopleClinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
- Where
- Beijing, Taiyuan, Tianjin, Xi'an
- Age
- 18 years and over
- People
- 45
- Run by
- Shanghai Pharmaceuticals Holding Co., Ltd
See details and how to joinNCT05145361 - Phase 2/3Taking peopleA Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Where
- Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Huizhou, Jinan, Jining, Kunming, Nanchang, Nanyang, Qingdao, Shenyang, Shenzhen, Shijiazhuang, Shiyan, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Xi'an, Xianyang, Yantai, Yongzhou, Zaozhuang, Zhengzhou, Zigong
- Age
- 18 years and over
- People
- 132
- Run by
- Shanghai Jiaolian Drug Research and Development Co., Ltd
See details and how to joinNCT06413654 - Phase 4Taking peopleTherapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
- Where
- Beijing
- Age
- 18 years to 65 years
- People
- 200
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT07410039 - Early phase 1Not yet taking people in ChinaUniversal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/ BCMA(QT-019C) in Patients With r/ r Neurological Autoimmune Diseases
- Where
- Tianjin
- Age
- 18 years and over
- People
- 15
- Run by
- Tianjin Huanhu Hospital
See details and how to joinNCT07392528 - Phase 1/2Taking peopleOfatumumab in AQP4-IgG Seropositive NMOSD
- Where
- Xi'an
- Age
- 18 years and over
- People
- 5
- Run by
- Tang-Du Hospital
See details and how to joinNCT05504694 - No phaseTaking peopleEfficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Where
- Xi'an
- Age
- 18 years to 75 years
- People
- 12
- Run by
- Tang-Du Hospital
See details and how to joinNCT07377305 - Early phase 1Taking peopleUniversal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases
- Where
- Tianjin
- Age
- 18 years and over
- People
- 12
- Run by
- Tianjin Huanhu Hospital
See details and how to joinNCT06939166 - Phase 1Taking peopleA Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 30
- Run by
- RenJi Hospital
See details and how to joinNCT06249438 - No phaseTaking peopleProtein A immuNoaDsorption for the Treatment of Acute Episodes of Neuromyelitis Optica Spectrum Disorder
- Where
- Guangzhou
- Age
- 18 years to 65 years
- People
- 144
- Run by
- Third Affiliated Hospital, Sun Yat-Sen University
See details and how to joinNCT06763848 - Early phase 1Not yet taking people in ChinaUniversal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 25
- Run by
- Xuanwu Hospital, Beijing
See details and how to joinNCT06485232 - Phase 2Taking peopleA Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
- Where
- Changsha
- Age
- 18 years to 65 years
- People
- 35
- Run by
- Guangzhou JOYO Pharma Co., Ltd
See details and how to joinNCT06697535 - Early phase 1Taking peopleSafety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 36
- Run by
- Tongji Hospital
See details and how to joinNCT04561557 - No phaseTaking peopleEfficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)
- Where
- Wuhan
- Age
- 18 years and over
- People
- 250
- Run by
- Tongji Hospital
See details and how to joinNCT06474520